ACC, AHA: No routine genetic or platelet-function testing for clopidogrel nonresponsiveness
from Heartwire via Medscape
The American College of Cardiology and the American Heart Association urge clinicians to adhere to the existing guidelines when using antiplatelet therapy but are reminding doctors about genetic variability altering clopidogrel metabolism, which in turn affects drug's inhibition of platelet function. The new report stops short of recommending routine genetic testing or assessments of platelet function because the evidence base is currently insufficient but does state that "genetic testing to determine if a patient is predisposed to poor clopidogrel metabolism (poor metabolizers) may be considered before starting clopidogrel in patients believed to be at moderate or high risk for poor outcomes."
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063